Changes in prescribing of inhaled corticosteroids (1999-2002) in Scotland

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 3, 2005, Pages 203-209

  Boyter, Anne C ^a   Steinke, Douglas T ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b Information and Statistics Division   (United Kingdom)

Author keywords

Consultations; Corticosteroids; Prescribing; Respiratory

Indexed keywords

BECLOMETASONE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSULTATION; DOSE RESPONSE; GENERAL PRACTITIONER; HUMAN; LONGITUDINAL STUDY; METERED DOSE INHALER; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REDUCTION; RESPIRATORY TRACT DISEASE; SEASONAL VARIATION; UNITED KINGDOM;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; BECLOMETHASONE; BUDESONIDE; DRUG COMBINATIONS; DRUG UTILIZATION REVIEW; ETHANOLAMINES; HUMANS; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOTLAND; TIME FACTORS;

EID: 14944382750     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1054     Document Type: Article

References (17)

1. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on the management of asthma. Thorax 2003; 58(Suppl. 1): 1-94.
2. The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52: 1S-27S.
3. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS, on behalf of the GOLD scientific committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
4. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK, on behalf of the ISOLDE study investigators. Randomised, double blind, placebo controlled study of fluticasone in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE study. Br Med J 2000; 320: 1297-1303.
5. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823.
6. Pauwels RA, Lofdhal CG, Laitinen LA, et al. For the European Respiratory Society Study on Chronic Obstructive Pulmonary Disease: long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. New Engl J Med 1999; 340: 1948-1953.
7. Calverley P, Pauwels R, Vestbo J, et al. For the TRISTAN (trial of inhaled steroids and long acting beta agonists) study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
8. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med. 1999; 160: 594-599.
9. Ringdal N, Chuchalin A, Chovan L, Tudoric N, Maggi E, Whitehead F. EDICT Investigators. Evaluation of different inhaled combination therapies (EDICT): a randomised double-blind comparison of Seretide (50/250 microg bd) Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate to severe asthma. Respir Med 2002; 96: 851-861.
10. Shrewsbury S, Pyke S, Britton M. Meta analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) Br Med J 2000; 320: 1368-1373.
11. Chapman KR, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Brown M. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999; 6: 45-51.
12. Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876-884.
13. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the diskus device for the treatment of asthma. Am J Resp Crit Care Med 2000; 161: 527-534.
14. Pang L, Knox AJ. Synergistic inhibition by β2-agonists and corticosteroids on tumor necrosis factor-α-induced interleukin-8 release from cultured human airway smooth muscle cells. Am J Respir Cell Mol Biol 2000; 23: 79-85.
15. Barnes PJ. Scientific rationale for inhaled combination therapy with long acting beta2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191.
16. Roth M, Johnson PRA, Rudiger JJ, et al. Interaction between glucocorticoids and β2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293-1299.
17. Fleming DM, Cross KW, Sunderland R, Ross AM. Comparison of the seasonal patterns of asthma identified in general practitioner episodes, hospital admissions, and deaths. Thorax 2000; 55: 662-665.